FDA does not concur, however, that an ANDA referencing Seroquel is precluded from including Table 2 or the suicidality warnings by virtue of AstraZeneca's 3-year exclusivity on certain indications for Seroquel XR. AstraZeneca filed its TRO papers on Wednesday morning and the parties met in court later that day. Later that night, Judge Howell issued her Order concluding that AstraZeneca "has not demonstrated a likelihood of success on the merits, particularly given the deference the Court must provide to agency actions and interpretations of its own organic statute, here, the [FDC Act]." Although Judge Howell denied AstraZeneca's TRO motion, FDA did not escape unscathed.